At SEB’s Nordic Seminar, CEO Mark Waugh presented OssDsign to investors just seven days after being appointed. We were impressed by his appearance. What made Mr. Waugh interested in joining was the PROPEL registry data (88.4% fusion in a complex cohort of 108 patients) and the large untapped opportunity in the orthobiologics market. We believe OssDsign found a CEO with relevant experience. There was no major news on the growth outlook for OssDsign.
LÄS MER
